Skip to main content

Home/ MaRS/ Group items tagged Axela Inc

Rss Feed Group items tagged

Cathy Bogaart

Nonclinical IVDs: Growing interest in a growing field - 0 views

  • Manufacturers of human IVD technologies have been contributing their skills and knowledge more and more to the nonclinical and agricultural diagnostic markets.
  • To learn more about why IVD manufacturers are making the switch from human diagnostics and testing to agricultural and other nonclinical diagnostics, IVD Technology editor Richard Park spoke with Rocky Ganske, president and CEO of Axela Inc. (Toronto)
    • Cathy Bogaart
       
      Axela is a MaRS client.
  • Our technology allows us to work directly in a variety of sample types that are difficult for other technologies to detect pathogens in without some additional sample preparation. So that led to people who were doing BSE (mad cow)–type testing asking if we could do tests for protein directly in matrices like milk or brain homogenate, and people asking for testing in plant extracts and things like that because other technologies don’t have that capacity.
  • ...2 more annotations...
  • Axela sells to the $20-billion life sciences market with its current platform, focusing first on protein-research applications, and enabling and capturing applications for downstream personalized medicine and human diagnostics.
  • Because it’s an attractive market, you see large diagnostic companies like Bayer Animal Health move some of its testing platforms that it would use for diagnostics into animal health testing
  •  
    MaRS Client, Axela, talks about moving from human protein testing into the agricultural markets -- the challenges and the opportunities.
Assunta Krehl

Axela announces bilateral agreement with diagnostic provider Salomao & Zoppi and Cria O... - 0 views

  •  
    MaRS tenant Axela Inc. pursues South American diagnostic assay market through MOU with Cria Opportunities Inc.
1 - 2 of 2
Showing 20 items per page